Bloomberg Law
Feb. 4, 2014, 10:07 PM

NIH, Industry Begin Partnership
For Early Discovery of Promising Treatments

In what he described as an “unprecedented” effort, National Institutes of Health Director Francis S. Collins said a partnership unveiled Feb. 4 aims to transform the model for identifying and validating the most promising drug targets.

The NIH has joined with 10 biopharmaceutical companies and several nonprofit organizations to form the Accelerating Medicines Partnership (AMP). The $230 million, five-year effort aims to distinguish biological targets of disease most likely to respond to new therapies and characterize biological indicators of disease, known as biomarkers.

As a result of technological revolutions in genomics, imaging and more, researchers have been able to identify ...